Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accessibility, ADCC, ADCP, adenosine, Adimab, afucosylated, agreeable, antigen, bankrupt, bargain, Bayer, biotech, Carlo, casdozokitug, cellular, Center, chemokine, chosen, CHS, cluster, companion, correlated, cytolytic, cytotoxicity, diagnostic, differentiation, discretion, Dolphin, DPF, elicit, enzyme, evidenced, explained, exploit, expressed, expression, extracellular, facilitate, fast, feet, filler, flat, forma, gave, goodwill, HCC, hepatocellular, Hudson, hybrid, immunoglobulin, immunological, Immunophage, immunosuppressive, inflammation, inhibitory, interleukin, irrespective, irrevocable, isotype, Israel, killer, Landlord, LaNova, lease, leased, LOQTORZI, lung, memory, metabolite, model, Monte, month, NK, nominal, nontransferable, orphan, overexpressed, perpetual, physiologic, Plaza, pregnancy, purport, PVRIG, regain, remeasured, residual, retroactive, Shionogi, space, square, suppressing, suppression, TD, tenant, tiered, tissue, Treg, Twin, uncured, undisputed
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view